Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

Biogen IncTrade
ProShares UltraPro S&P500Trade

Price performance (Past 24H)

Key statistics

Biogen Inc vs ProShares UltraPro S&P500 — how do they compare? Biogen Inc trades at $206.92 (market cap $30.13B), while ProShares UltraPro S&P500 trades at $154.39. Which is the better fit depends on your goals.

BIIBUPRO
Market Cap
$30.13B
Sector
HealthLeveraged / Inverse
52-Week High
$216.63$155.10
52-Week Low
$128.93$89.29
Enterprise Value
$37.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

ProShares UltraPro S&P500

UPRO trades at $154.38, down 0.39% on the day, while maintaining a bullish technical outlook with strong moving average signals. The leveraged ETF tracking the S&P 500 faces mixed sentiment as oscillators show neutral readings amid record market highs. Recent institutional activity includes Bay Colony Advisors establishing a new position, indicating professional interest despite valuation concerns in the broader market.

The ETF's performance remains tied to S&P 500 momentum, with technical strength supporting near-term upside potential. However, elevated RSI levels and market-wide valuation concerns present headwinds. The absence of traditional fundamental metrics for this leveraged product emphasizes its tactical rather than long-term investment nature.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About ProShares UltraPro S&P500

UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.

Read more on UPRO